OOIR: Observatory of International Research

Papers

(The H4-Index of Experimental Hematology & Oncology is 34. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Allogeneic stem cell transplantation may overcome the adverse impact of myelofibrosis on the prognosis of myelodysplastic syndrome	136
Next-generation sequencing for MRD monitoring in B-lineage malignancies: from bench to bedside	135
Prospective pharmacotyping of urothelial carcinoma organoids for drug sensitivity prediction – feasibility and real world experience	120
Efficacy and safety of immune checkpoint inhibitors in metastatic penile squamous cell carcinoma: a retrospective multicenter analysis	110
Telomeres, telomerase, and cancer: mechanisms, biomarkers, and therapeutics	103
New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities	97
Current approaches to develop “off-the-shelf” chimeric antigen receptor (CAR)-T cells for cancer treatment: a systematic review	79
Cytokine-based models for efficient differentiation between infection and cytokine release syndrome in patients with hematological malignancies	71
The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives	61
Suppression of CYLD by HER3 confers ovarian cancer platinum resistance via inhibiting apoptosis and by inducing drug efflux	59
cGAS-ISG15-RAGE axis reprogram necroptotic microenvironment and promote lymphatic metastasis in head and neck cancer	59
Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD	58
Targeting ST8SIA6-AS1 counteracts KRASG12C inhibitor resistance through abolishing the reciprocal activation of PLK1/c-Myc signaling	54
Correction: Breast cancer heterogeneity and its implication in personalized precision therapy	53
HIV associated lymphoma: latest updates from 2023 ASH annual meeting	52
Enhanced cellular therapy: revolutionizing adoptive cellular therapy	51
Correction: Unraveling the structures, functions and mechanisms of epithelial membrane protein family in human cancers	51
Emerging therapeutic frontiers in cancer: insights into posttranslational modifications of PD-1/PD-L1 and regulatory pathways	50
Tumor battlefield within inflamed, excluded or desert immune phenotypes: the mechanisms and strategies	48
Targeting hepcidin in colorectal cancer triggers a TNF-dependent-gasdermin E-driven immunogenic cell death response	48
Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors	47
Exploiting E3 ubiquitin ligases to reeducate the tumor microenvironment for cancer therapy	47
Comprehensive analysis of clinical, pathological, and genomic characteristics of follicular helper T-cell derived lymphomas	43
Myeloid-derived suppressor cells in hematologic malignancies: two sides of the same coin	42
Multi-omic profiling of the leukemic microenvironment shows bone marrow interstitial fluid is distinct from peripheral blood plasma	42

Recent updates on central nervous system prophylaxis in patients with high-risk diffuse large B-cell lymphoma	41
All-in-one CRISPR/Cas-engineered glucocorticoid-receptor knock-out EBV-gp350-CAR knock-in T cells are potent and resistant to dexamethasone	40
Breast cancer heterogeneity and its implication in personalized precision therapy	39
Role of m6A writers, erasers and readers in cancer	38
IL-39 promotes chronic graft-versus-host disease by increasing T and B Cell pathogenicity	37
Hetrombopag plus porcine ATG and cyclosporine for the treatment of aplastic anaemia: early outcomes of a prospective pilot study	37
CAR-macrophages targets CD26 to eliminate chronic myeloid leukemia stem cells	37
Novel agents and regimens in relapsed or refractory peripheral T-cell lymphoma: latest updates from 2023 ASH annual meeting	35
Matching-adjusted indirect comparison of efficacy and safety of lisocabtagene maraleucel and mosunetuzumab for the treatment of third-line or later relapsed or refractory follicular lymphoma	35
CD19/CD22 CAR-T-cell cocktail therapy following autologous transplantation is an optimizing strategy for treating relapsed/refractory central nervous system lymphoma	34
Single-cell transcriptome analysis reveals stem cell-like subsets in the progression of Waldenström’s macroglobulinemia	34